Advertisement
Advertisement
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
14.15
USDSponsored
+0.49
+3.59%
May 13, 16:00 UTC -4
Closed
Pre-Market
14.12
-0.04
-0.25%
CTNM Earnings Reports
Positive Surprise Ratio
CTNM beat 3 of 9 last estimates.
33%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.55
Implied change from Q1 26 (Revenue/ EPS)
--
/+41.03%
Implied change from Q2 25 (Revenue/ EPS)
--
/-11.29%
Contineum Therapeutics, Inc. Class A Common Stock earnings per share and revenue
On May 05, 2026, CTNM reported earnings of -0.39 USD per share (EPS) for Q1 26, beating the estimate of -0.54 USD, resulting in a 28.06% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.82% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.55 USD, with revenue projected to reach -- USD, implying an increase of 41.03% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Contineum Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Contineum Therapeutics, Inc. Class A Common Stock reported EPS of -$0.39, beating estimates by 28.06%, and revenue of $0.00, 0% as expectations.
How did the market react to Contineum Therapeutics, Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved up 3.82%, changed from $14.39 before the earnings release to $14.94 the day after.
When is Contineum Therapeutics, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Contineum Therapeutics, Inc. Class A Common Stock's next earnings report?
Based on 6
analysts, Contineum Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$0.55 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement